Product category:
Laboratory and scientific professional organisations
News Release from: Cancer Research UK
Edited by the Laboratorytalk Editorial
Team on 18 January 2008
CRT licenses antibody technology to
Glycart
Specialist oncology-focused development and commercialisation company has granted an exclusive worldwide licence to Glycart Biotechnology to develop a preclinical antibody for the treatment of cancer
The licensed antibody selectively binds to a cell surface-presented protein that is over-expressed in certain types of cancer including colorectal cancer The antibody was originally developed by Cancer Research UK
Glycart will use its proprietary Glycomab technology to enhance the in vivo efficacy of the antibody.
A research collaboration between CRT, Glycart and the University of Oxford has been established to investigate the potential efficacy of the glyco-engineered antibody in pre-clinical studies Phil L'Huillier, CRT's director of business management, said: "This is a significant step forward in the development of this technology as a therapeutic agent.
"We're very pleased that Glycart is taking this exciting antibody forward and we look forward to the development of a therapeutic that will help treat bowel cancer more efficiently.".
• Cancer Research UK: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
